ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 25 of 68
Up
JMBS 2021, 6(5): 178–183
https://doi.org/10.26693/jmbs06.05.178
Clinical Medicine

Insulin-Like Growth Factor-1 and Left Ventricle Remodeling in Patients with Hypertension with Abdominal Obesity

Koval S. M., Reznik L. A., Starchenko T. G., Penkova M. Yu.
Abstract

The purpose of the work is to study the role of insulin-like growth factor-1 in the mechanisms of left ventricular remodeling in patients with arterial hypertension with abdominal obesity and arterial hypertension with normal body weight. Materials and methods. The study included 42 patients with arterial hypertension and abdominal obesity and 22 patients with arterial hypertension and normal body weight. All patients underwent general clinical laboratory and instrumental examination. The structural parameters of the heart were determined using echocardiographic studies. To assess the geometric rearrangement of the left ventricle, the relative thickness of its walls was calculated. Determination of the level of insulin-like growth factor-1 in serum was performed using enzyme-linked immunosorbent assay. Results and discussion. According to echocardiographic studies, left ventricular hypertrophy was diagnosed in 30 patients (71.4%) with arterial hypertension and obesity and in 9 (40.9%) patients with normal body weight (p <0.05). The advantage of hypertrophic types in the structural reconstruction of the heart and the formation of unfavorable types of geometry of the left ventricle in the presence of abdominal obesity in the subjects was found. It was found that in arterial hypertension with abdominal obesity, high levels of insulin-like growth factor-1 were found with normal geometry of the left ventricle, and with concentric hypertrophy and eccentric hypertrophy, a gradual probable decrease in this growth factor was observed and adhered to its comparison with the norm. The attention is drawn not only to the gradual decrease in insulin-like growth factor-1 from normal geometry to concentric and eccentric geometry, but also to the probable differences between this growth factor in concentric geometry and eccentric geometry, indicating the role of insulin-like growth factor-1 deficiency in cardiac remodeling. In normal weight hypertension, probable differences in this growth factor are obtained only between normal and eccentric left ventricular geometry. Сonclusion. Thus, the data obtained may indicate differences in the course of arterial hypertension, aggravated by abdominal obesity, in comparison with patients with hypertension with normal body weight. It is the association of arterial hypertension with abdominal obesity that causes a decrease in the synthesis of insulin-like growth factor-1, as a result of which there is an accelerated development of the pathological geometry of the left ventricle with the subsequent manifestation of heart failure. These results allow us to expand our understanding of the mechanisms of the formation of cardiac damage in patients with arterial hypertension and especially when it is combined with obesity

Keywords: arterial hypertension, abdominal obesity, insulin-like growth factor-1, cardiac remodeling

Full text: PDF (Ukr) 317K

References
  1. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-3104. https://www.ncbi.nlm.nih.gov/pubmed/30165516. https://doi.org/10.1093/eurheartj/ehy339
  2. Mіtchenko OІ, Romanov VYu, Yanovs'ka KO. Visokij kardіovaskulyarnij rizik u hvorih z arterіal'noyu gipertenzіeyu ta ozhirіnnyam [High cardiovascular risk in patients with arterial hypertension and obesity]. Zdorov'ya Ukraїni. 2012; Tematichnij nomer: 24-25. [Ukrainian]
  3. Druzhilov MA, Kuznecova TYu. Geterogennost' fenotipov ozhireniya v otnoshenii serdechno-sosudistogo riska [Heterogeneity of obesity phenotypes against cardiovascular risk]. Kardiovaskulyarnaya terapiya i profilaktika. 2019; 18(1): 161-7. https://doi.org/10.15829/1728-8800-2019-1-161-167
  4. Rigobon AV, Kanagasabai T, Taylor VH. Obesity moderates the complex relationships between inflammation, oxidative stress, sleep quality and depressive symptoms. BMC Obesity. 2018; 5: 32. https://www.ncbi.nlm.nih.gov/pubmed/30524737. https://www.ncbi.nlm.nih.gov/pmc/articles/6276225. https://doi.org/10.1186/s40608-018-0208-2
  5. Sun T, Xie J, Zhu L, Han Z, Xie Y. Left ventricular hypertrophy and asymptomatic cardiac function impairment in chinese patients with simple obesity using echocardiography. Obes Facts. 2015; 8(3): 210-219.
  6. https://www.ncbi.nlm.nih.gov/pubmed/26087902. https://www.ncbi.nlm.nih.gov/pmc/articles/5644870. https://doi.org/10.1159/000435795
  7. Koval' SN, Reznik LA, Starchenko TG. Vozrastnye osobennosti urovnej IFR-1 u bol'nyh gipertonicheskoj bolezn'yu [Age features of IFR-1 levels in patients with hypertensive disease]. Ukrains'kij kardіologіchnij zhurnal. 2012; 1: 25. [Russian]
  8. Koval SM, Rieznik LA, Starchenko TH, Penkova MY, Kurinna OH. Modulating influence of insulin-like Growth Factor-1on structural-functional heart indices in patients with essential hypertension and type 2 diabetes mellitus. 18 World Congress insulin resistens, USA; 2020 Sep 25-25. 2020. p. 0101.
  9. Hoffmann K, Nagel AJ, Tanabe K, Fuchs J, Dehlke K, Ghamarnejad O, et al. Markers of liver regeneration - the role of growth factors and cytokines: a systematic review. J BMC Surgery. 2020; 20(1): 31. https://www.ncbi.nlm.nih.gov/pubmed/32050952. https://www.ncbi.nlm.nih.gov/pmc/articles/7017496. https://doi.org/10.1186/s12893-019-0664-8
  10. Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016; 14: 3. https://www.ncbi.nlm.nih.gov/pubmed/26733412 https://www.ncbi.nlm.nih.gov/pmc/articles/4702316. https://doi.org/10.1186/s12967-015-0762-z
  11. Aguirre GA, González-Guerra JL, Espinosa L, Castilla-Cortazar I. Insulin-Like Growth Factor 1 in the Cardiovascular System. Rev Physiol Biochem Pharmacol. 2018; 175: 1-45. https://www.ncbi.nlm.nih.gov/pubmed/29294200. doi: 10.1007/112_2017_8
  12. WHO. Obesity: Prevention and managing the global epidemic. Technical Report Series 894. Geneva: WHO; 2000.
  13. Svіshchenko EP Bezrodna LV, Mіshchenko LA, Sіrenko YuM, Kupchins'ka OG, Radchenko GD. Klіnіchnij protokol nadannya medichnoi dopomogi pacіentam іz gіpertonіchnoyu hvoroboyu (esencіal'noyu AG). Sercevo-sudinnі zahvoryuvannya. Klasifіkacіya, standarti dіagnostiki ta lіkuvannya [Clinical Protocol for Medical Assistance to Patients with Hypertonic Disease (Essential AG). Cardiovascular disease. Classification, diagnostic and treatment standards]. Eds by VM Kovalenko, MІ Lutayi, YuM Sіrenko, OS Sichov. K: MORІON; 2016. s. 59-63. [Ukrainian]
  14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2): 79-108. https://www.ncbi.nlm.nih.gov/pubmed/16458610. https://doi.org/10.1016/j.euje.2005.12.014
  15. Gennadinik AG, Nelaeva AA. Rol' insulinopodobnogo faktora rosta-1 v metabolizme, regulyacii kletochnogo obnovleniya i processah stareniya [The role of insulin-like growth factor-1 in metabolism, regulation of cellular update and aging processes]. Ozhirenie i Metabolizm. 2010; 2: 10-15. [Russian]. https://doi.org/10.14341/2071-8713-5203
  16. Galderisi M, Vitale G, Lupoli G, Barbieri M, Varricchio G, Carella C, et al. Inverse association between free insulin-like growth factor-1 and isovolemic relaxation in arterial systemic hypertension. Hypertension. 2001; 38(4): 840-845. https://www.ncbi.nlm.nih.gov/pubmed/11641296. https://doi.org/10.1161/hy1001.091776
  17. Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, et al. IGF-1 Expression in Infarcted Myocardium and MGF E Peptide Actions in Rat Cardiomyocytes in Vitro. Mol Med. 2009 May-Jun; 15(5-6): 127-35. https://www.ncbi.nlm.nih.gov/pubmed/19295919. https://www.ncbi.nlm.nih.gov/pmc/articles/2656994. https://doi.org/10.2119/molmed.2009.00012
  18. Palmen M, Daemen MJ, Bronsaer R, Dassen WR, Zandbergen HR, Kockx M, et al. Cardiac remodeling after myocardial infarction is impaired in IGF-1 deficient mice. Cardiovasc Res. 2001; 50(1): 516-24. https://www.ncbi.nlm.nih.gov/pubmed/11376627. https://doi.org/10.1016/S0008-6363(01)00237-1
  19. Zakirova NE, Nikolaeva IE, Zakirova AN. Rol' insulinopodobnogo faktora rosta 1 v razvitii processov remodelirovaniya miokarda u zhenshchin s arterial'noj gipertoniej i metabolicheskim syndromom [The role of an insulin-like growth factor 1 in the development of myocardial remodeling processes in women with arterial hypertension and metabolic syndrome]. CardioSomatika. 2018; 9(3): 18-24. [Russian]. https://doi.org/10.26442/2221-7185_2018.3.18-24
  20. Jing Z, Hou X, Wang Y, Yang G, Wang B, Tian X, et al. Association between insulin-like growth factor-1 and cardiovascular disease risk: evidence from a meta-analysis. Int J Cardiol. 2015, 198: 1-5. https://www.ncbi.nlm.nih.gov/pubmed/26143182. https://doi.org/10.1016/j.ijcard.2015.06.114